Samsung Sets New Standard for Flagship Mobile Processors with Exynos 2100
12.1.2021 18:05:00 EET | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today announced the Exynos 2100 through its first virtual event, Exynos On 2021 (www.youtube.com/samsung). The new mobile processor is the company’s first premium 5G-integrated mobile processor built on the most advanced 5-nanometer (nm) extreme ultra-violet (EUV) process node.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210112005748/en/
Exynos 2100 introduced by Dr. Inyup Kang (Photo: Business Wire)
“Our Exynos team has been committed to creating premium mobile computing experiences by bringing innovations to processors that are at the heart of today’s smart devices,” said Inyup Kang, president of System LSI Business at Samsung Electronics. “Today we are delighted to introduce the Exynos 2100, our most advanced mobile processor yet. Armed with powerful processing technologies and an advanced 5G modem on a power-efficient 5nm process node, Exynos 2100 will set a new standard for tomorrow’s flagship mobile devices.”
“At Samsung Electronics, we are dedicated to providing innovative technologies and services with our flagship devices to deliver the ultimate mobile experience to our customers,” said Kyeongjun Kim, Executive Vice President and head of Mobile R&D Office at Mobile Communications Business, Samsung Electronics. “With powerful processing, fast 5G connectivity, and intelligent AI-acceleration, the Exynos 2100 offers the utmost performance that meets the stringent quality standards and requirements for our next generation smartphone.”
“The evolution of technologies such as 5G, advanced graphics and machine learning have been critical in enabling new mobile experiences,” said Paul Williamson, vice president and general manager, Client Line of Business at Arm. “Arm and Samsung have collaborated closely to incorporate Arm’s powerful next-generation compute and graphics platform, at the heart of the Samsung Exynos 2100. As a result of our partnership, we are able to maximize performance and make these experiences a reality in next-generation mobile devices while delivering exceptional battery life.”
The chip’s computation and graphic processing performance have been improved and refined to surpass the power user’s performance expectations. As Samsung’s first 5G-integrated flagship mobile processor, the Exynos 2100 is built on an advanced 5nm EUV process technology that allows up to 20-percent lower power consumption or 10-percent higher overall performance than the 7nm predecessor. For further enhancement, the chip offers improved cache memory utilization and a stronger scheduler. The octa-core CPU comes in an improved tri-cluster structure made up of a single powerful Arm® Cortex®-X1 core that runs at up to 2.9GHz, three high-performing Cortex-A78 cores and four power-efficient Cortex-A55 cores delivering more than 30-percent enhancement in multi-core performance than the predecessor.
The Arm Mali™-G78, which supports the latest APIs such as Vulkan and OpenCL, improves graphic performance by more than 40-percent for visually stunning and seamless graphics, enabling the most immersive on-screen mobile experiences yet, including gaming and AR/VR or MR(Mixed Reality). The Exynos 2100 also integrates advanced multi-IP governor (AMIGO) technology, which overlooks and optimizes power usages of CPU, GPU, and other processes, allowing longer use time even with intense on-screen activities. With such comprehensive efforts to increase energy efficiency of its products across software and hardware technologies, Samsung also continues its strive to help minimize the carbon footprint of tomorrow’s mobile devices.
AI capabilities will also enjoy a significant boost with the Exynos 2100. The newly-designed tri-core NPU has architectural enhancements such as minimizing unnecessary operations for high effective utilization and support for feature-map and weight compression. Exynos 2100 can perform up to 26-trillion-operations-per-second (TOPS) with more than twice the power efficiency than the previous generation. With on-device AI processing and support for advanced neural networks, users will be able to enjoy more interactive and smart features as well as enhanced computer vision performance in applications such as imaging.
The Exynos 2100’s advanced image signal processor (ISP) supports camera resolutions of up to 200-megapixels (Mp). It can connect up to six individual sensors and is able to process four concurrently for richer multi-camera experiences. With a multi-camera and frame processor (MCFP), the ISP can combine feeds from multiple cameras to improve zoom performance, enhance image quality for ultra-wide shots and more. With AI acceleration, the ISP offers a content-aware feature that quickly and seamlessly recognizes scenes, faces and objects and optimally adjusts the camera settings to capture the image with fuller detail.
The Exynos 2100’s integrated 5G modem supports 5G’s sub-6GHz and mmWave spectrums from 2G GSM/CDMA, 3G WCDMA and 4G LTE, for strong network coverage and reliability. The modem delivers a maximum downlink speed of up to 5.1-gigabits per second (Gbps) in sub-6-gigahertz (GHz) and 7.35Gbps in mmWave, or up to 3.0Gbps in 4G networks with 1024 Quadrature Amplitude Modulation (QAM) support.
The Exynos 2100 is currently in mass production.
For more information about Samsung’s Exynos products, please visit http://www.samsung.com/exynos.
|
Process |
5nm |
AI |
26 TOPS |
|
Multi-core |
Octa-core |
CPU (Main) |
Arm Cortex-X1 (2.9GHz) |
|
CPU (Sub) |
Arm Cortex-A78 and Cortex-A55 |
GPU |
Arm Mali-G78 |
|
Connectivity |
5G (sub-6GHz/mmWave), 4G LTE (1024 QAM), 3G WCDMA, 2G GSM/CDMA |
Memory |
LPDDR5 (51.2GB/s) |
|
Storage |
UFS 3.1, UFS 2.1 |
Camera (Rear) |
200MP |
|
Video (Encoding) |
4K UHD 120fps |
Video (Decoding) |
8K 60fps |
# # #
* Editor's Note: Actual performance may vary depending on device and user environment.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005748/en/
Contact information
Ujeong Jahnke
Samsung Semiconductor Europe GmbH
Tel. +49(0)89-45578-1000
Email: sseg.comm@samsung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom